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Background: The chemokine CCL2 has an important role in the recruitment of inflammatory cells into the central
nervous system (CNS). A transgenic mouse model that overexpresses CCL2 in the CNS shows an accumulation of
leukocytes within the perivascular space surrounding vessels, and which infiltrate into the brain parenchyma
following the administration of pertussis toxin (PTx).
Methods: This study used contrast-enhanced magnetic resonance imaging (MRI) to quantify the extent of blood–brain
barrier (BBB) disruption in this model pre- and post-PTx administration compared to wild-type mice. Contrast-enhanced
MR images were obtained before and 1, 3, and 5 days after PTx injection in each animal. After the final imaging session
fluorescent dextran tracers were administered intravenously to each mouse and brains were examined histologically for
cellular infiltrates, BBB leakage and tight junction protein.
Results: BBB breakdown, defined as a disruption of both the endothelium and glia limitans, was found only in
CCL2 transgenic mice following PTx administration and seen on MR images as focal areas of contrast
enhancement and histologically as dextrans leaking from blood vessels. No evidence of disruption in endothelial
tight junctions was observed.
Conclusion: Genetic and environmental stimuli were needed to disrupt the integrity of the BBB in this model of
neuroinflammation.
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Multiple sclerosis (MS) is an autoimmune disease of the
central nervous system (CNS), wherein inflammation,
demyelination, and blood–brain barrier (BBB) disruption
occurs. The magnetic resonance imaging (MRI) contrast
agent gadolinium diethylenetriaminepentaacetate (Gd-
DTPA) does not move through the intact BBB. Follow-
ing intravenous administration of Gd-DTPA, a signal
increase on T1-weighted MR images is observed where
the BBB is disrupted at sites of inflammation [1,2].
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distribution, and reproduction in any mediumenhanced MRI [6-9] have both shown that opening of
the BBB is an early event in the development of the
disease, though the exact mechanism that causes BBB
disruption is currently unknown.
The chemokine CCL2, previously known as monocyte
chemoattractant protein-1, has a role in the recruitment of
inflammatory cells into the CNS [10,11]. CCL2 is expressed
within active and chronic MS lesions [11-14]. Astrocytes
[13-15] and microglia [16] are believed to be sources of
CCL2. Leukocytes accumulate in the perivascular space
between the endothelium and glia limitans (formed by
astrocytic foot processes) in transgenic mice that overex-
press CCL2 in the CNS [17,18]. This transgenic mouse
model is a unique experimental system for studying the
infiltration of inflammatory cells across the endothelium
and glia limitans of the BBB, which is not possible inentral Ltd. This is an Open Access article distributed under the terms of the
creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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across the BBB following pertussis toxin (PTx) admin-
istration along with an upregulation of proinflamma-
tory cytokines and metalloproteinase genes [18]. This
metalloproteinase-dependent migration of inflammatory
cells across the glia limitans supports the hypothesis that
BBB leakage is present in this model. PTx increases the
permeability of the BBB in animal models of EAE and
results in a more severe disease course [20].
The integrity of the BBB in mice overexpressing CCL2
in the CNS pre- and post-PTx compared to wild-type
mice is currently unknown. Information regarding BBB
permeability to small and large molecules in this model
of inflammation may provide insights into the individual
and combined effects of CCL2 upregulation and PTx
administration, and thus into the overall mechanism of
neuroinflammation. T1-weighted contrast-enhanced MRI
was used to determine how treatment with PTx affects
BBB permeability in PTx and vehicle treated CCL2 trans-
genic and wild-type mice. This study seeks to determine
the permeability of a small molecular sized MR contrast
agent (550D) and large dextran tracer (70kD) across the
BBB in the CCL2 transgenic mouse model of inflamma-
tion and considers the potential implications of these find-
ings in encephalomyelitis.Figure 1 (A) Sagittal MR image of a mouse brain showing the slice
positioning for MR imaging. The slice furthest anterior was
positioned 1 mm posterior to the notch at the olfactory bulbs
indicated by the dotted line. (B) Coronal T2-weighted MR images
(TE = 80.4 ms) were used to define the area of the brain omitting the
enhancing ventricles seen in (C).Methods
Animal model
Female and male MBP-JE transgenic mice 11–13 weeks
old (bred at the University of Southern Denmark) over-
expressing CCL2 in the CNS under control of a myelin
basic protein promoter, [17,18] were given a single intraper-
itoneal injection of PTx (Cedarlane Laboratories, Hornby,
ON) at a dose of 10 μg/kg (n=9) or 20 μg/kg (n=7). PTx
stock solution (50 μg/mL in phosphate-buffered saline) was
diluted to 1 μg/mL or 2 μg/mL using Hanks’ balanced salt
solution (HBSS; Invitrogen Corporation, Burlington, ON)
for doses of 10 μg/kg or 20 μg/kg respectively. Transgenic
mice that received the equivalent volume of HBSS (n=6)
served as controls. Similarly, a group of female and male
wild-type B6D2F1 mice 11 weeks old (Charles River
Canada, Saint Constant, QC) were given an injection of
either 10 μg/kg PTx (n = 6), 20 μg/kg PTx (n = 5), or
HBSS (n = 5) as. The B6D2F1 mice are the most appro-
priate control strain for this experiment, since the trans-
genic mice were generated by injecting transgenes into
the eggs from a cross between C57BL/6 J × DBA/2
mice as previously described [17] and are maintained
by brother-sister mating. All mice were housed in
pathogen-free conditions with free access to food and
water, and were weighed and monitored daily. All animal
procedures were approved by the Animal Care Committee
at the University of Manitoba.MR imaging
T2-weighted MR images and T1-weighted contrast-
enhanced MR images of the brain were obtained using a
Bruker Biospec imager with a 7 T/21 cm magnet and a
quadrature volume coil 2 cm in diameter. Mice were
anesthetized by ventilating with 5 % isoflurane in 2:3 O2/
N2O for induction and maintained using 1.5-2.0 % iso-
flurane delivered via a nose cone during imaging. Eight
T2-weighted MR images spanning the brain were obtained
using a multi-slice multi-echo (TE=26.8 ms, TR=2500 ms,
matrix size = 256×256, FOV=2.5×2.5 cm2, slice thickness =
0.75 mm, interslice gap=0.25 mm, 8 echoes, 2 averages)
sequence. The eight slices were chosen to cover as much
of the brain as possible without compromising the signal
to noise ratio of the images. Slices were reproducibly
positioned with exactly 1 mm between the notch poster-
ior to the olfactory bulbs and the edge of the first slice
(Figure 1A). A set of T1-weighted images (TE = 13.0 ms,
TR = 600 ms, matrix size = 256×256, FOV= 2.5×2.5 cm2,
slice thickness = 0.75 mm, interslice gap = 0.25 mm, slice
positions identical to those of the T2-weighted images,
4 averages) was then acquired over 10 min. A bolus of
0.4 mmol/kg Gd-DTPA (dimeglumine salt, Berlex Canada,
0.5 mmol/mL, 550D) was injected through a 30 gauge tail
vein cannula while the mouse remained undisturbed in
Figure 2 (A) Calculated percent enhancement map (fourth slice
from the anterior end of the brain; 12mm×12mm) taken from a
transgenic mouse pre-PTx injection and (B) a transgenic mouse
5 days post 20 μg/kg PTx injection selecting only the pixels with
20 % or more enhancement. (C) Corresponding histograms of the
percent intensity within the ROI, where open circles are pre-PTx and
filled circles are post-PTx. The threshold used to select enhancing pixels
is indicated.
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weighted images was obtained immediately following
the Gd-DTPA administration, using the same acquisi-
tion parameters. Linear phase encoding was used, result-
ing in the maximum signal being detected 5 min after
starting the acquisition.
The animals were examined with MRI pre-PTx/HBSS
injection and at days 1, 3, and where possible at day 5
post-injection. Approximately half the transgenic and
wild-type mice did not have an imaging session at day 5
post-PTx/HBSS administration due to technical problems
with the MR system (Table 1).
MR image analysis
The contrast enhancement on T1-weighted images was
quantified by calculating percent difference maps as ((post-
contrast image – pre-contrast image)/pre-contrast image)×
100%. T2-weighted images (TE=80.4 ms) (Figure 1B) were
used to define the region of interest (ROI) outlining the
brain and omitting the enhancing ventricles (Figure 1C)
using Marevisi (National Research Council, Canada) soft-
ware. These ROIs were superimposed onto the calculated
maps of percent enhancement (Figure 2), and histograms of
the number of pixels within the ROI versus intensity were
generated.
Tissue processing
After the last imaging session on day 5 post-PTx/HBSS in-
jection, a solution of 70kD lysine-fixable dextran conju-
gated to fluorescent Texas Red (25 mg/mL in phosphate
buffered saline, (0.25 g/kg, 3 moles dye/mol dextran;
Molecular Probes, Eugene, OR) was injected into the left
ventricle of the heart of each mouse. After one minute
the mouse was perfusion-fixed using phosphate-buffered
10 % formalin. The imaged region of the brain was sliced
into four sections 2 mm thick. Brain sections were embed-
ded in paraffin and tissue sections 6 μm thick were cutTable 1 The number of transgenic and wild-type mice
that underwent MR imaging at each time point and final
histological analysis
Group Pre-injection Post-injection
Initial
total
MRI Day 1 Day 3 Day 5
MRI MRI MRI Histology
HBSS tg 6 6 6 6 4 6
wt 5 5 5 5 3 5
Low PTx tg 9 9 9 8 4 8
wt 6 6 6 6 3 6
High PTx tg 7 5 7 6 5 6
wt 5 5 5 5 2 5
tg: transgenic; wt: wild-type; HBSS: treated with Hanks' Balanced Salt Solution;
Low PTx: treated with pertussis toxin at 10 μg/kg; High PTx: treated with
pertussis toxin at 20 μg/kg.onto glass slides. Laminin was detected by incubating
sections overnight using anti-laminin (1:50; rabbit poly-
clonal antibody Ab-1; NeoMarkers, Fremont, CA) followed
by biotin-conjugated secondary antibody, streptavidin-
peroxidase, and diaminobenzidine. Sections were incu-
bated with anti-glial fibrillary acidic protein (GFAP; 1:250;
rabbit polyclonal antibody; DakoCytomation, Mississauga,
ON) to detect astrocytes followed by counter staining for
30 seconds using 4',6-diamidino-2-phenyl indole (DAPI;
1:1000; Sigma, St. Louis, MO) to visualize nuclei. Activated
microglia and macrophages were labeled using Bandeira
simplicifolia 1 lectin (1:50; Sigma-Aldrich, Saint Louis, MO)
and visualized using diaminobenzidine. Adjacent sections
were stained with H&E to visualize general histological
features. Additional 12 μm thick frozen sections were
stained for tight junction protein claudin-5 using rabbit
anti-claudin-5 (1:100; Invitrogen, Camarillo, CA, USA),
Alexa Fluor donkey anti-rabbit IgG secondary antibody
(1:300; Invitrogen), and leukocyte marker CD45 using
rat anti-mouse CD45-PE conjugated antibody (1:300; Bio-
Legend, San Diego, CA, USA) followed by counter staining
with DAPI.Statistics
Data are reported as mean± standard error of the mean.
ANOVA was carried out for calculated difference maps
of each slice at day 3 post-PTx/HBSS injection followed
Figure 4 (A) The average percentage of enhancing pixels within each
brain slice that had intensity enhancement 20 % or greater at day 3
post injection for transgenic and wild-type mice. (B) A representative
set of calculated difference maps obtained from a transgenic mouse
following 20 μg/kg PTx on day 3. Significant differences were found in
the 6 most posterior slices for both transgenic (tg) low and high PTx
compared to both wild-type (wt) and tg HBSS. * differs from wt,
p< 0.05, ** p< 0.01, *** p< 0.001 and + differs from tg HBSS, p< 0.05,
++ p< 0.01, +++ p< 0.001.
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for multiple comparisons. Calculated difference maps of
the posterior 6 slices at each time point and percent
change in weight between transgenic and wild-type mice
before and after PTx/HBSS administration were compared
statistically using ANOVA followed by Fisher’s PLSD post
hoc test.
Results
One transgenic mouse that received an initial dose of
20 μg/kg PTx died under anesthetic during imaging on
day 3 and a second transgenic mouse that received an
initial dose of 10 μg/kg PTx died on day 5.
MR imaging
Focal areas of enhancement on contrast-enhanced MR
images were scattered throughout coronal brain slices of
CCL2 transgenic mice that had been injected with PTx
(Figures 3, 4). Enhancement was observed predominantly
in basal areas of the brain and surrounding the ventricles
with fewer regions of enhancement in the cortex. The
number and area of focal enhancements increased in
more posterior brain slices with greatest enhancement in
the midbrain and very little enhancement in the frontal
lobes (Figure 4). ANOVA was significant (p< 0.001) for
slices 3 to 8 and post hoc comparisons were significant
in these slices for both transgenic mice that received low
and high dose PTx compared to both wild-type mice and
transgenic mice that received HBSS. No focal enhance-
ment was observed on contrast-enhanced T1-weighted
images within the brains of CCL2 transgenic mice thatFigure 3 Representative percent enhancement maps calculated from coronal MR images (12mm×12mm) of the fourth anterior slice taken from
wild-type and transgenic mice that were administered HBSS, 10 μg/kg PTx, or 20 μg/kg PTx. MR images were obtained pre-injection, and at days
1, 3 and 5 post-injection from the same animal.
Figure 5 The percentage of pixels in the posterior 6 slices of the
brain showing a 20 % or greater increase in intensity on calculated
percent enhancement maps for (A) wild-type and (B) transgenic
mice pre-injection and days 1, 3 and 5 post HBSS, post 10 μg/kg PTx,
and post 20 μg/kg PTx. * differs from HBSS, p< 0.01.
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of PTx or HBSS (Figure 3).
The histograms obtained from the maps of percent
enhancement for wild-type mice and transgenic mice
receiving HBSS or before PTx injection showed a normal
distribution of intensities, with the number of pixels cen-
tered on 2–4 % intensity and typically ranging between±
20 % intensity (Figure 2). For transgenic mice following
PTx administration, the histograms showed a distribution
that was skewed to higher intensity (Figure 2) and had a
range of intensities extending past 20 %. A relative meas-
ure of BBB disruption was determined by calculating the
percentage of pixels with a contrast enhancement above
20 % within the brain on calculated percent difference
images. Only the posterior six slices were used in these
calculations because the slices located more anterior had
little contrast enhancement. PTx administration at either
dose in CCL2 transgenic mice caused an increase in con-
trast enhancement that was significant at day 3 (Figure 5).
Three days after the administration of PTx at either 10 or
20 μg/kg, there was a significant increase in the percentage
of pixels within the brain showing enhancement above
20 % (p< 0.01 and p< 0.005 respectively, vs mice given
HBSS, Figure 5). No significant differences were found
between CCL2 transgenic mice pre-PTx/HBSS adminis-
tration and following HBSS administration at days 1, 3,
or 5 or between wild-type mice pre- and post-PTx/HBSS.
Contrast-enhanced MR images of transgenic mice pre-
PTx/HBSS had a greater percentage of pixels with enhance-
ment greater than 20 % (p< 0.0001) than was observed for
wild-type mice.
Clinical signs
There were no significant differences in the change in
weight between any of the groups of mice day 1 post-PTx/
HBSS injection. Subsequently, a loss in weight was observed
only in CCL2 transgenic mice after PTx injection, with
greater losses in mice receiving the higher dose. At days 2,
3, 4, and 5 post-PTx/HBSS injection there was a signifi-
cantly greater loss in weight in CCL2 transgenic mice
injected with PTx at low (p< 0.05) and high (p< 0.005)
dose compared to wild-type mice and transgenic mice
injected with HBSS. Changes in weight were not signifi-
cantly different between CCL2 transgenic mice injected
with HBSS and wild-type mice at any time point. A signifi-
cant dose-dependent difference in weight loss was present
between transgenic mice that received the high and low
doses of PTx at days 3 (p< 0.05) and 4 (p< 0.05). The
largest weight loss was at day 5 in transgenic mice that
were administered the low dose PTx (average 5.5 %) and
the high dose PTx (average 9.6 %). On average, the trend
was that transgenic mice receiving the high dose PTx
lost twice as much weight as transgenic mice receiving
the low dose PTx. Inactivity was additionally observed intransgenic mice post-PTx injection and death in the case
of two transgenic mice.Histology
Mice were perfusion-fixed following the last imaging
session and tissue sections of the brains were examined
for inflammatory cell infiltrates on H&E and lectin stained
sections. Sites of BBB opening were revealed by the pres-
ence of fluorescent dextrans, which were observed by epi-
fluorescence microscopy. Large numbers of inflammatory
cells and fluorescent dextrans were observed within the
perivascular spaces of vessels in the brains of all CCL2
transgenic mice (Figure 6). These inflammatory cells
surrounded vessels in the cerebral cortex, striatum and
white matter, as well as large vessels in the medulla and
cerebellar white matter. Inflammatory cells were promin-
ent in the subarachnoid space surrounding large vessels
and followed along their superficial sites of penetration.
Figure 6 Histological sections stained with H&E to show general features of inflammation and corresponding unstained sections to visualize
regions of fluorescence due to dextrans surrounding blood vessels. Sections were taken from representative wild-type and transgenic mice
following HBSS or PTx administration and correspond to the final imaging session on day 5 post injection. Original magnification 100×. Additional
lectin stained sections identify activated microglia and macrophages from corresponding transgenic mice at 400× magnification. Arrows indicate
lectin-labeled cells within the brain parenchyma.
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inflammatory cells, rather the inflamed vessels were ran-
domly distributed. Approximately 25 % of the perivascu-
lar inflammatory cells were labeled with BS-1 lectin
(Figure 6) and no further lectin-positive cells were found
beyond the perivascular cluster of cells. Tissue sections
from CCL2 transgenic mice also revealed strong claudin-5
staining of the endothelium of vessels with perivascular
accumulation of inflammatory cells.
Following PTx administration, inflammatory cells were
observed within the brain parenchyma surrounding veins
in CCL2 transgenic mice. Fluorescent dextrans were also
present in the parenchyma (Figure 6). Rare cells within
the parenchyma beyond the cluster of perivascular inflam-
matory cells were labeled with BS-1 lectin. In transgenic
mice that received HBSS, inflammatory cells remained
confined to the perivascular space with no evidence of dex-
trans in brain parenchyma (Figure 6). Based on nuclear
morphology approximately 5 % of the infiltrated cells were
neutrophils. No inflammatory cells were observed within
the perivascular space of brain sections of wild-type mice
following PTx or HBSS (Figure 6). Additionally, no BS-1
lectin-labeled cells were present within the brain tissue
with the exception of surface ependymal cells.
Histologically identifiable perivascular inflammation cor-
responded well to sites of Gd-DTPA enhancement on the
MR images. However, the distribution of these cells and
the spread of dextrans were much more confined than the
areas of MR enhancement. Staining for nuclei with DAPI
confirmed the presence of large numbers of inflammatorycells within the perivascular space. The endothelial barrier
was visualized by staining for laminin and dextrans were
present across the endothelial barrier in all groups of
transgenic mice (Figure 7A). The overlay of GFAP immuno-
labeling with fluorescent dextrans around inflamed vessels
of the brains from CCL2 transgenic control mice showed
that dextrans were confined to the perivascular space, and
they did not cross the astrocytic barrier (Figure 7C). How-
ever, in transgenic mice that received PTx, dextrans moved
beyond the astrocytic barrier (Figure 7B). The injection of
PTx had no effect on the distribution or intensity in the
staining for the tight junction protein claudin-5 in CCL2
transgenic mice (Figure 8).Discussion
The breakdown of the BBB and the presence of CCL2
both have a role in the initiation of disease signs in EAE
and MS. Therefore, the effects of upregulated CCL2 before
and after PTx injection were studied in this model using
T1-weighted contrast-enhanced MR imaging. As previ-
ously described, the upregulation of CCL2 within the CNS
of mice causes inflammatory cells to cross the endothelial
cell barrier and accumulate within the perivascular space
of vessels in the brain; [17,18] but this did not produce
any clinical signs of disease. In the present study, contrast-
enhanced MR images did not show any evidence of an
increase in BBB permeability to a 550D Gd contrast
agent in the absence of treatment with PTx. Similiarly,
histological examination did not show the presence of
Figure 8 Representative tissue sections stained for tight junction
protein claudin-5 (green), leukocyte marker CD45 (red), and DAPI (blue)
from (A) a wild-type control mouse, (B) a CCL2 transgenic control
mouse, and (C) a CCL2 transgenic mouse post-high dose PTx.
Figure 7 (A) Brain section from a CCL2 transgenic mouse that was
administered 10 μg/kg PTx and immunolabeled for laminin (brown)
shows that the dextrans (red fluorescence) have crossed the basal
lamina of the endothelial layer. (B) Fluorescence microscopic imaging
of a vessel that is leaking dextrans (red) with corresponding staining
for GFAP (green) and DAPI (blue) from a CCL2 transgenic mouse
that was administered 20 μg/kg PTx. Overlay shows that the
dextrans have moved past the astrocytic barrier. (C) Comparable
images of a non-leaking vessel shows dextrans confined to the
perivascular space. Original magnification 100×.
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vessels following intravenous administration.
There was no evidence of endothelial dysfunction in
vessels surrounded by a perivascular accumulation of in-
flammatory cells in CCL2 transgenic mice. Staining for
tight junction protein claudin-5 demonstrated no differ-
ence between CCL2 transgenic mice pre- or post-PTx
injection. These observations do not rule out endothelial
dysfunction at a previous point in time, as well as the
possibility that extravasation occurs in a manner thatdoes not involve disruption of tight junctions. In a previ-
ous study of mice with EAE using electron microscopy,
there was no evidence of loss of integrity of the BBB
during leukocyte migration [21]. This provides support-
ing evidence for a transcellular migration pathway
across the endothelium, with tight junctions remaining
intact. Considering a paracellular migration pathway,
CCL2 has been found to have a role in the alteration of
tight junctions in the endothelium both in vitro and
in vivo [22-24]. A decrease in expression of the tight
junction proteins occludin, claudin-5, ZO-1, and ZO-2
was observed following intracerebral injection of CCL2
in mice [23]. The effect of CCL2 on a BBB co-culture
model with astrocytes was increased barrier permeabil-
ity when endothelial cells were CCR2+/+ and astrocytes
were CCR2−/−, but not when endothelial cells were
CCR2−/− and astrocytes were CCR2+/+ [23]. These results
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cause increased BBB permeability.
The transgenic mouse model used in this study is not a
perfect physiologic system as it overexpresses CCL2 result-
ing in a 100,000 fold increase in the mRNA level of CCL2
within the brain (unpublished data by Toft-Hansen et al).
Despite this limitation, the CCL2 transgenic mouse
model represents a good experimental system in which
leukocytes accumulate in the perivascular space, and
parenchymal infiltration can be stimulated using PTx. In
the present study, no signs of BBB disruption could be
visualized on calculated contrast-enhanced MR maps
even though inflammatory cells were found to have crossed
the endothelium and accumulated in the perivascular
space. The overexpression of CCL2 alone was therefore
insufficient to produce BBB breakdown, defined in this
study as a disruption of the endothelium and glia limit-
ans. The accumulation of fluorescent dextrans in the
perivascular space in CCL2 transgenic mice before the
administration of PTx or HBSS confirms that the endo-
thelial barrier is permeable to the tracer; however, dex-
trans were not found to cross the astrocytic barrier. The
more confined spread of dextrans in comparison to
the areas of MR enhancement suggests either greater
sensitivity using MR imaging or greater diffusion of the
smaller Gd-DTPA molecule. These observations from
histology and contrast-enhanced MR imaging indicate
that in the CCL2 transgenic mice there is increased per-
meability through the endothelial barrier while the astro-
cytic barrier remains intact and prevents the movement of
inflammatory cells, 70kD dextran tracer, and 550D Gd-
DTPA contrast agent into the brain parenchyma.
Wild-type mice did not show any signs of BBB disruption
following PTx administration. Other studies have shown
that PTx causes increased permeability to horseradish per-
oxidase tracer in a monolayer of brain capillary endothelial
cells [25]. Enhanced leakage across the microvasculature in
mice due to PTx was also observed following histamine
administration [26,27] as well as during the onset of EAE
[26]. However, in a previous study of a SJL/J mouse model
of EAE, control mice treated with PTx did not show any
indications of BBB permeability [28].
When CCL2 transgenic mice were treated with PTx, in-
flammatory cells infiltrated the brain tissue surrounding
blood vessels, dextran tracer leaked into the brain paren-
chyma, and activated microglia/macrophages were found
present in brain parenchyma. The maximum area of focal
enhancements on contrast-enhanced MR images was found
at day 3 following PTx treatment in CCL2 transgenic mice,
suggesting a transient BBB opening in this model, and the
decreased contrast enhancement at day 5 indicates that the
BBB disruption was beginning to resolve by this time.
Metalloproteinases degrade the extracellular matrix com-
ponents of the BBB, and metalloproteinase genes werepreviously found to be significantly upregulated in this
CCL2 transgenic mouse model following PTx adminis-
tration [18]. This occurs along with an increase in proin-
flammatory cytokines IL-1β and TNF-α, which play a
role in leukocyte migration into the CNS [18]. CCL2
transgenic mice showed increased levels of MMP-10,
MMP-12, IL-1β and TNF-α even before PTx injection,
but the results of the present study show that this is not
sufficient to cause BBB permeability. The addition of
PTx to the model is the additional stimulus needed to
cause BBB breakdown and stimulate the cells accumu-
lated in the perivascular space to cross the astrocytic cell
barrier and enter brain parenchyma.
The CCL2 transgenic mice in our study exhibited se-
vere disruption in the BBB that allowed a 70kD dextran
tracer to move into the brain parenchyma. Permeability
to a large tracer indicates that other large molecules from
the blood can escape into the CNS during the inflamma-
tory process. Large serum proteins, such as thrombin, may
in turn cause local damage to brain tissue and exacerbate
extracellular water accumulation [29-31]. Permeability of
the BBB to large molecules in this transgenic mouse
model of brain inflammation has important implications
for understanding the consequences of and developing
treatments for encephalomyelitis.
Conclusions
The combination of genetic and environmental stimuli
resulted in a disruption of the integrity of the BBB in this
model of neuroinflammation. The addition of PTx to
transgenic mice that overexpresses CCL2 in the CNS
resulted in leukocyte migration into brain parenchyma
along with increased permeability of tracer and MR con-
trast agent across the endothelium and glia limitans.
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